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Summary 
The Norwegian Scientific Committee for Food Safety (Vitenskapskomiteen for mattrygghet, 
VKM) has, at the request of the Norwegian Food Safety Authority (Mattilsynet; NFSA), 
assessed the risk of "other substances" in food supplements and energy drinks sold in 
Norway. VKM has assessed the risk of doses given by NFSA. These risk assessments will 
provide NFSA with the scientific basis while regulating "other substances" in food 
supplements. 
"Other substances" are described in the food supplement directive 2002/46/EC as substances 
other than vitamins or minerals that have a nutritional and/or physiological effect. It is added 
mainly to food supplements, but also to energy drinks and other foods. In this series of risk 
assessments of "other substances" the VKM has not evaluated any claimed beneficial effects 
from these substances, only possible adverse effects. 
The present report is a risk assessment of specified doses of beta-alanine in food 
supplements, and it is based on previous risk assessments and articles retrieved from 
literature searches. 
According to information from NFSA, beta-alanine is an ingredient in food supplements sold 
in Norway. NSFA has requested a risk assessment of beta-alanine: 1000, 1500 and 
2000 mg/day from food supplements.  
Beta-alanine is a non-essential, non-proteogenic naturally occurring beta amino acid. Beta-
alanine is a component of the naturally occurring peptides carnosine, anserine and balenine. 
Supplementation with beta-alanine leads to an increased production of the peptide 
carnosine, which is found in high concentrations in the skeletal muscle of both vertebrates 
and non-vertebrates. Data suggest that beta-alanine functions as a small molecule 
neurotransmitter and should join the ranks of the other amino acid neurotransmitters. 
The only observed adverse effect from beta-alanin supplementation in humans is transient 
(1-2 hours) paraesthesia and flushing. Paraesthesia is characterised by a stinging or prickling 
sensation in the skin. There is no evidence that the paraesthesia in the skin is harmful in any 
way. Long-term studies in humans were not found. Four small human clinical studies have 
been included in this risk assessment. The occurrence of paraesthesia apparently is 
dependent on the magnitude of the individual doses that the daily dose is split into. Single 
doses of beta-alanine of 10 mg/kg bw (700 mg in a 70 kg person) or more provoked 
transient paraesthesia. Symptom occurrence and severity increased with the dose. Repeated 
intakes of 5 mg beta-alanine/kg bw or less taken with >2 hours intervals did not induce 
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paraesthesia. Haematology and plasma clinical chemistry was found normal after daily doses 
of 2.8 g and 3.2 g for 4 weeks in healthy adults. Apart from occasional paraesthesia, a daily 
dose of 6.4 g for up to seven weeks did not induce any adverse clinical effects in healthy 
adults of 80 kg, corresponding to a dose of 5.6 g per day in a 70-kg person.  
We are not aware of any data indicating that children and adolescents are more vulnerable 
than adults for supplementation with beta-alanine on a per kg bw basis. 
No relevant animal studies were identified.  
VKM concludes that: 
 In adults (≥18 years), the specified doses 1000, 1500 and 2000 mg/day of beta-
alanine in food supplements are unlikely to cause adverse health effects provided 
that beta-alanine is consumed with maximum 5 mg/kg bw per intake and a minimum 
of 2 hours between the intakes.  
  
 In adolescents (14 to <18 years) and children (10 to <14 years) the specified doses 
1000, 1500 and 2000 mg/day of beta-alanine in food supplements are unlikely to 
cause adverse health effects provided that beta-alanine is consumed with maximum 5 
mg/kg bw per intake and a minimum of 2 hours between the intakes.  
Children younger than 10 years were not within the scope of the present risk 
assessment. 
Short summary  
At the request of the Norwegian Food Safety Authority, the Norwegian Scientific Committee 
for Food Safety (VKM) has characterised the risk of specified doses of beta-alanine in food 
supplements. VKM concludes that: 
 In adults (≥18 years), the specified doses 1000, 1500 and 2000 mg/day of beta-
alanine in food supplements are unlikely to cause adverse health effects provided 
that beta-alanine is consumed with maximum 5 mg/kg bw per intake and a minimum 
of 2 hours between the intakes.  
 
 In adolescents (14 to <18 years) and children (10 to <14 years) the specified doses 
1000, 1500 and 2000 mg/day of beta-alanine in food supplements are unlikely to 
cause adverse health effects provided that beta-alanine is consumed with maximum 5 
mg/kg bw per intake and a minimum of 2 hours between the intakes.  
 
 
VKM Report 2017:13  8 
 
Key words: Beta-alanine, food supplement, adverse health effect, negative health effect, 
Norwegian Food Safety Authority, Norwegian Scientific Committee for Food Safety, other 




VKM Report 2017:13  9 
Sammendrag på norsk 
På oppdrag for Mattilsynet har Vitenskapskomiteen for mattrygghet (VKM) vurdert risiko ved 
tilsetting av "andre stoffer" i kosttilskudd og energidrikk som selges i Norge. VKM har 
risikovurdert ulike bruksdoser oppgitt fra Mattilsynet. Disse risikovurderingene vil gi 
Mattilsynet vitenskapelig grunnlag for å regulere "andre stoffer" i kosttilskudd. 
"Andre stoffer" er beskrevet i kosttilskuddirektivet (2002/46/EF) som stoffer som har en 
ernæringsmessig eller fysiologisk effekt, og som ikke er vitaminer og mineraler. De tilsettes i 
hovedsak i kosttilskudd, men også i energidrikker og andre næringsmidler. I disse 
risikovurderingene har VKM kun vurdert mulige negative helseeffekter, ikke potensielle 
gunstige helseeffekter. 
Denne rapporten er en risikovurdering av beta-alanin, og den er basert på tidligere 
risikovurderinger og artikler hentet fra litteratursøk.  
Ifølge informasjon fra Mattilsynet er betaalanin en ingrediens i kosttilskudd som selges i 
Norge. Oppdraget fra Mattilsynet var å risikovurdere inntak på 1000, 1500 og 2000 mg/dag 
betaalanin i kosttilskudd. 
Betaalanin er en ikke-essensiell, ikke-proteogen naturlig forekommende beta-aminosyre. 
Betaalanin inngår i naturlig forekommende peptider som karnosin, anserin og balenin. 
Tilskudd av betaalanin fører til økt produksjon av peptidet karnosin. Karnosin fins i høye 
konsentrasjoner i skjelettmuskulatur hos både virveldyr og ikke-virveldyr. Data tyder på at 
betaalanin fungerer som nevrotransmitter. 
Det eneste negative helseeffekten som er observert hos mennesker ved tilskudd med 
betaalanin er forbigående parestesier og flushing, det vil si lokal rødhet og varmefølelse. 
Parestesier gir en stikkende og prikkende følelse i huden, som kan oppleves som ubehagelig 
når den er sterk. Det finnes ikke dokumentasjon for at parestesier er skadelig, ut over 
ubehaget.  
Kun fire små kliniske studier er inkludert i denne risikovurderingen. Det er ikke funnet 
langtidsstudier. Inntak av enkeltdoser med betaalanin på 10 mg/kg kroppsvekt (700 mg i en 
70 kg person) eller mer, førte til parestesier. Symptomgraden økte med dosen. Gjentatte 
inntak av 5 mg betaalanin per kg kroppsvekt tatt med mer enn 2 timers mellomrom 
fremkalte ikke parestesier. Hematologi og klinisk-kjemiske undersøkelser var normale etter 
daglige doser på henholdsvis 2,8 g og 3,2 g betaalanin i 4 uker hos friske voksne. En daglig 
dose på 6,4 g i inntil 7 uker til friske voksne på 80 kg, svarende til 5,6 g for en person på 
70 kg, ga ikke andre negative kliniske effekter enn noen tilfeller av parestesi, som synes å 
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avhenge av i hvor store enkeltdoser dagsdosen deles opp. Vi har ikke funnet data som kan 
tyde på at barn og ungdom har lavere toleranse enn voksne for tilskudd med betaalanin 
dosert på basis av kroppsvekt. 
Det ble ikke identifisert noen relevante dyrestudier. 
Vitenskapskomiteen for mattrygghet (VKM) konkluderer med at: 
 For voksne (≥18 år) er det usannsynlig at de spesifiserte dosene på 1000, 1500 og 
2000 mg/dag betaalanin i kosttilskudd vil forårsake negative helseeffekter, forutsatt 
at hvert inntak er maksimalt 5 mg/kg kroppsvekt og at varigheten mellom inntakene 
er minimum 2 timer. 
 For ungdom (14 til <18 år) og barn (10 til <14 år) er det usannsynlig at de 
spesifiserte dosene på 1000, 1500 og 2000 mg/dag betaalanin i kosttilskudd vil 
forårsake negative helseeffekter, forutsatt at hvert inntak er maksimalt 5 mg/kg 
kroppsvekt og at varigheten mellom inntakene er minimum 2 timer. 
Barn under 10 år inngår ikke i dette oppdraget. 
Kort sammendrag  
Vitenskapskomiteen for mattrygghet (VKM) har på oppdrag for Mattilsynet vurdert risiko ved 
inntak spesifikke doser av betaalanin i kosttilskudd. VKM konkluderer med at: 
 For voksne (≥18 år) er det usannsynlig at de spesifiserte dosene på 1000, 1500 og 
2000 mg/dag betaalanin i kosttilskudd vil forårsake negative helseeffekter, forutsatt 
at hvert inntak er maksimalt 5 mg/kg kroppsvekt og at varigheten mellom inntakene 
er minimum 2 timer. 
 For ungdom (14 til <18 år) og barn (10 til <14 år) er det usannsynlig at de 
spesifiserte dosene på 1000, 1500 og 2000 mg/dag betaalanin i kosttilskudd vil 
forårsake negative helseeffekter, forutsatt at hvert inntak er maksimalt 5 mg/kg 




VKM Report 2017:13  11 
Abbreviations and glossary 
Abbreviations 
AESAN  - Spanish Agency for Food Safety and Nutrition 
bw  - body weight 
EFSA  - European Food Safety Authority 
IOM  - Institute of Medicine, USA 
mrg  - mas-related gene 
NFSA  - Norwegian Food Safety Authority [Norw.: Mattilsynet] 
UL  - tolerable upper intake level 
VKM  - Norwegian Scientific Committee for Food Safety [Norw.: Vitenskapskomiteen 
for Mattrygghet] 
WHO  - World Health Organization 
Glossary 
"Other substances": a substance other than a vitamin or mineral that has a nutritional or 
physiological effect (European Regulation (EC) No. 1925/2006, Article 2; http://eur-
lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32006R1925&from=en).  
"Negative health effect" and "adverse health effect" are broad terms. The World Helath 
Organization (WHO) has established the following definition of "adverse effect": a change in 
morphology, physiology, growth, development, reproduction or life span of an organism, 
system or (sub)population that results in an impairment of functional capacity, an 
impairment of the capacity to compensate for additional stress, or an increase in 
susceptibility to other influences (WHO, 1994). 
An adverse event is considered serious if it results in death, is life-threatening, requires or 
prolongs hospitalisation, is a congenital anomaly or birth defect, is a persistent or significant 
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Background as provided by the 
Norwegian Food Safety Authority 
"Other substances" are substances other than vitamins and minerals, with a nutritional 
and/or physiological effect on the body. "Other substances" are mainly added to food 
supplements, but these may also be added to other foods and beverages, such as sports 
products and energy drinks. Ingestion of these substances in high amounts presents a 
potential risk for consumers.  
In Norway, a former practice of classification of medicines had constituted an effective 
barrier against the sale of potentially harmful "other substances". Ever since this practice 
was changed in 2009, it has become challenging to regulate and supervise foods with added 
"other substances". Meanwhile, in the recent years, the Norwegian market has witnessed a 
marked growth in the sales of products containing "other substances". In 2011, food 
supplements containing "other substances" constituted more than 50% of the market share. 
While within the European Economic Area, these substances fall under the scope of the 
European Regulation (EC) No. 1925/2006 on the addition of vitamins, minerals and certain 
other substances to foods and the European Regulation (EC) No 258/97 concerning novel 
foods and novel food ingredients, "other substances" remain largely unregulated. In order to 
ensure safe use of "other substances" many countries have regulated their use at a national 
level. For example, Denmark regulates these substances in a positive list i.e. a list of 
substances with maximal daily doses, permitted for use in food supplements and other foods 
(FVM, 2014).  
The Norwegian Food Safety Authority (NFSA) is working on the establishment of a regulation 
on the addition of "other substances" to foods at a national level. The regulation will include 
a list of substances with permitted maximal doses, based on the substances and doses found 
in products on the Norwegian market. In preparation for a regulation, NFSA has therefore 
requested the Norwegian Scientific Committee for Food Safety (VKM) to assess the safety of 
"other substances" found on the Norwegian market. NFSA, in consultation with the industry, 
has compiled a list of "other substances" found in products marketed in Norway. Only 
substances with a purity of minimum 50% or concentrated 40 times or more have been 
included in the list. Substances regulated by other legislations like those for novel foods, 
food additives, aromas, foods for special medical purposes, etc. have been excluded from 
the list.  
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Terms of reference as provided by the 
Norwegian Food Safety Authority 
The Norwegian Food Safety Authority (NFSA) requested the Norwegian Scientific Committee 
for Food Safety (VKM) to assess the safety of beta-alanine in food supplements at the 
following doses: 1000, 1500 and 2000 mg/day. 
NFSA requested VKM to assess the safety of "other substances" (in accordance with the 
guidance document developed in Phase 2) for the specified doses (Phase 3). 
The safety assessments for "other substances" present in food supplements shall be carried 
out for the general population, age 10 years and older.  
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1 Introduction 
"Other substances" are described in the food supplement directive 2002/46/EC as substances 
other than vitamins or minerals that have a nutritional and/or physiological effect, and may 
be added to food supplements or e.g. energy drinks.  
This risk assessment regards the substance beta-alanine per se, and no specific products. 
In this series of risk assessments of "other substances" the VKM has not evaluated any 
claimed beneficial effects from these substances, but merely possible adverse effects at 
specified doses used in Norway.  
According to information from the Norwegian Food Safety Authority (NFSA), beta-alanine is 
an ingredient in food supplements sold in Norway. NFSA has requested a risk assessment of 
the intake of 1000, 1500 and 2000 mg beta-alanine per day from food supplements. The 
total beta-alanine exposure from other sources than food supplements is not included in the 
risk assessment. 
Foods rich in beta-alanine are in particular those made from skeletal muscle of vertebrates 
as well as non-vertebrates. The amount of beta-alanine intake from food is unknown.  
Beta-alanine is a naturally occurring amino acid, with the amino group at the beta-position 
from the carboxylate group. Beta-alanine is not used in the biosynthesis of any major 
proteins or enzymes and is therefore described as non-proteogenic. Beta-alanine is a 
component of the naturally occurring peptides carnosine (beta-alanyl-L-histidine), anserine 
(beta-alanyl-N(pi)-methyl-L-histidine) and balenine (beta-alanyl-N tau-methyl histidine) and 
is also a metabolite of pantothenic acid (vitamin B5). Moreover, beta-alanine is produced by 
breakdown of pyrimidine nucleotides. Beta-alanine is produced endogenously in the liver of 
many animals, but at varying rates. In humans, beta-alanine is mostly acquired through 
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2 Hazard identification and 
characterisation 
2.1 Literature 
This risk assessment is based on previous risk assessments of beta-alanine, as well as 
scientific papers retrieved from systematic literature searches.  
 Previous risk assessments 
Risks related to beta-alanine have previously been evaluated by VKM in 2011 and the 
Scientific Committee of the Spanish Agency for Food Safety and Nutrition (ASEAN) for use in 
food supplements in 2012. 
VKM report on risk categorisation of amino acids. Norway, 2011 
In 2011, VKM conducted a risk categorisation of about 30 amino acids and amino acid 
compounds based on potential health risks related to high intakes of the amino acids (VKM, 
2011).  
According to the report, beta-alanine provided as gelatine capsules in single doses of > 
10 mg/kg bw per day (> 700 mg in a 70 kg person) resulted in transient paraesthesia. Beta-
alanine consumed from foods as carnosine (e.g. meats or chicken broth) up to 40 mg/kg bw 
per day did not induce adverse effects. Based on these results, which were retrieved from 
Harris et al. (2006), beta-alanine was grouped as a low risk amino acid. It was, however, 
emphasised that the VKM report from 2011 had several limitations and could only be 
regarded as an initial screening and not as risk assessment of the many amino acids.  
Report of the Scientific Committee of the Spanish Agency for Food Safety and 
Nutrition (AESAN) on the use conditions for certain substances other than 
vitamins, minerals and plants in food supplements. Spain, 2012. 
In 2012, AESAN stated that doses of beta-alanine above 10 mg/kg bw have been observed 
to provoke adverse effects. The adverse effects are associated with its potential to induce 
paraesthesia, characterised by an increase in the sensitivity of the nociceptive neurons, the 
transmitters of neuropathic pain, causing a stinging sensation and redness on the skin 
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(Crozier et al., 2007; Harris et al., 2006; Sale et al., 2010). The studies by Harris et al (2006) 
(see section 2.4.1) are discussed. 
The plasma kinetics and the incidence of symptoms similar to paraesthesia were monitored 
in a randomised, simple blinded test that involved gradual release over time of a beta-
alanine supplement (Decombaz et al., 2012). Healthy adults (n = 11) received three 
treatments: 1.6 g of gradually-released beta-alanine orally, the same dose administered 
normally (bolus), and a placebo. Urine and plasma samples were taken during the 6 hours 
following the administration of each treatment and a questionnaire was given to the 
participants. The gradually-released beta-alanine caused lower and later plasma peaks, 
together with reduced loss through urine indicating a greater retention of beta-alanine. The 
standard form of administering beta-alanine led to paraesthesia, whereas the gradually-
released dose and the placebo behaved similarly and triggered no symptoms. The authors 
concluded that higher doses (>10 mg/kg bw) of gradually-released beta-alanine can be 
taken without the risk of paraesthesia (Decombaz et al., 2012).  
In conclusion, AESAN (2012) considers that the precautions to be adopted when beta-
alanine is used as a food supplement are due to its potential to induce paraesthesia. High 
doses of beta-alanine (above 10 mg/kg bw per day) may produce paraesthesia. Moreover, 
individuals with a predisposition to paraesthesia should refrain from taking this food 
supplement. 
 Literature search 
Literature searches were performed in MEDLINE and EMBASE in order to retrieve 
publications on adverse effects caused by beta-alanine. Both databases were searched to 
ensure comprehensive study retrieval. The literature search for human studies was 
conducted on 13 September 2016, and the search for animal studies was conducted on 28 
October 2016. The strategies for the searches are outlined in Appendix 1. 
2.1.2.1 Publication selection and data extraction 
The literature search for human studies identified 367 articles, and the literature search for 
animal studies identified 395 articles. In the primary screening, titles and abstracts of all 
unique publications retrieved were independently screened against the inclusion criteria.  
Inclusion criteria: 
 An adverse effect/adverse effects in relation to beta-alanine alone is addressed 
 Route of exposure for humans is oral 
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 Route of exposure for animals is oral, in addition, subcutaneous exposure is included 
if the toxicokinetics are equal as by oral exposure 
 Human studies are performed in apparently healthy individuals or patient groups 
assumed to have normal alanine absorption and metabolism 
 Animal model studies address adverse effects relevant to human health 
In vitro studies were not included. 
The inclusion criteria checklist was developed by members of the Panel on Food Additives, 
Flavourings, Processing Aids, Materials in Contact with Food and Cosmetics and the Panel on 
Nutrition, Dietetic Products, Novel Food and Allergy. Titles and abstracts that did not fulfil 
the inclusion criteria were excluded from further screening. In situations where it was 
unclear whether the publication was of relevance to the current risk assessment, it was 
retained for further screening. The primary screening was performed independently by two 
persons.  
The papers that passed the primary screening were reviewed in full text against the same 
inclusion criteria by the author of this report. 
In the search aimed at human studies, the screening of titles and abstracts resulted in 25 full 
text articles, while the full-text review resulted in 3 relevant articles. In addition, one 
publication from a manual search was identified and reviewed. In the literature search aimed 
at retrieving animal studies, no titles and abstracts passed the primary screening. Thus, in 
total, four human studies was found relevant and included in the results in this report (see 
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Human studies: n = 342 
Animal studies: n=395 
 
 










Figure 2.1.2.1-1: Flowchart for publication selection for beta-alanine.  
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2.2 General information 
 Chemistry 
Beta-alanine is a non-essential amino acid that is formed by the degradation of dihydrouracil. 
It may also be formed by degradation of the dipeptides carnocine, anserine and balenine, 
where carnosine is the major souce for beta-alanine in vivo. The molecular formula is 
C3H7NO2, and the CAS number is 107-95-9. The structural formula is shown in figure 2.2.1-1. 
 
Figure 2.2.1-1: Structural formula of beta-alanine. 
 Occurrence 
Beta-alanine is a component of the naturally occurring peptides carnosine, anserine and 
balenine. Carnosine is found in high concentrations in the skeletal muscle of both vertebrates 
and non-vertebrates, where it is believed to function as a small molecule neurotransmitter. 
Meat and fish are rich food sources of beta-alanine. 
2.3 Absorption, distribution, metabolism and excretion 
 In humans 
Beta-alanine is a naturally occurring amino acid in which the amino group is at the beta-
position from the carboxylate group. Beta-alanine is a component of the naturally occurring 
peptides carnosine (beta-alanyl-L-histidine), anserine (beta-alanyl-N(pi)-methyl-L-histidine) 
and balenine (beta-alanyl-N tau-methyl histidine) and also of pantothenic acid (vitamin B5), a 
component of coenzyme A. Carnosine is the most abundant beta-alanine containing peptide 
and is a cytoplasmic dipeptide found in high concentrations in skeletal muscle, as well as in 
the central nervous system (Sale et al., 2010). Beta-alanine is the rate-limiting precursor of 
carnosine synthesis (Sale et al., 2010). This means that endogenous carnosine levels are 
limited by the amount of available beta-alanine. Carnosine concentrations in human skeletal 
muscle is in the magnitude of 20 mmol/kg dry muscle (Mannion et al., 1992). Data suggest 
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that beta-alanine functions as a small molecule neurotransmitter and should join the ranks of 
the other amino acid neurotransmitters (Tiedje et al., 2010).  
Under normal conditions, beta-alanine can undergo a transamination reaction with pyruvate 
to form malonate-semialdehyde and L-alanine. The malonate semialdehyde can then be 
converted into malonate via malonate-semialdehyde dehydrogenase. Malonate is then 
converted into malonyl-CoA and enter fatty acid biosynthesis.  
Beta-alanine is produced endogenously in the liver of many animals, but at varying rates. 
Increasing beta-alanine concentration has been found to increase the concentration of 
carnosine in the skeletal muscle of both vertebrates and non-vertebrates. The species having 
the highest skeletal muscle beta-alanine containing dipeptide concentrations are those 
whose muscles are exposed to frequent bouts of hypoxia, such as diving whales, or those 
who depend upon anaerobic exercise for survival, such as hunting or escaping animals (Abe, 
2000). High beta-alanine containing dipeptides have been shown in several species involved 
in athletic competition, such as horses, greyhounds, camels and, indeed, humans (Dunnett 
and Harris, 1997; Harris et al., 1990). Moreover, the distribution of beta-alanine containing 
carnosine varies in skeletal muscle across species and between different muscle fibre types 
in the same species. The beta-alanine containing peptide carnosine acts as an intracellular 
proton chelator and hence pH buffer (Severin et al., 1953) and a potent antioxidant (Kohen 
et al., 1988). 
2.4 Toxicological data/Adverse effects  
The only adverse effect from beta-alanine reported in literature is paraesthesia (i.e. a 
tingling or prickling sensation) in the skin. The paraesthesia has mainly been experienced in 
the face, neck and back of hands, but also on the upper trunk and lower back. It may vary in 
severity from a light, almost pleasant tingling to a strongly uncomfortable feeling. 
Paraesthesia is commonly experienced in individuals consuming single doses of 10 mg beta-
alanine/kg bw or more (Trexler et al., 2015). It appears to be dose-dependent both with 
regard to occurrence and severity (Harris et al., 2006; see also below). However, after an 
interval of 2-3 hrs or more, another dose can be taken without significantly increased risk of 
paraesthesia (Harris et al., 2006). Thus, two different safety issues emerge: one is the 
magnitude of the individual dose, the other is the magnitude of the total daily intake. 
Regarding the individual dose, for most individuals, a dose of 400 mg beta-alanine ingested 
acutely was symptom free, and this dose has frequently been used in various studies (e.g. 
(Baguet et al., 2009; Derave et al., 2007; Harris et al., 2006)). With 500 mg doses, no 
symptoms were reported and treatment identification was not different between verum and 
placebo (Van Thienen et al., 2009). With 800 mg doses (10 mg/kg bw), Harris et al. (2006) 
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acknowledged ‘‘mild symptoms of flushing’’ in about 25% of about 50 subjects, while Hill et 
al. (2007) report that symptoms were ‘‘infrequent and mild when they occurred’’. With a 1.6-
g dose, symptoms were recorded as ‘‘significant’’ in three of four subjects (Harris et al., 
2006), and one third of 11 participants in the study reported by Decombaz et al. (2012) had 
moderate to low-intensity symptoms. Brisola et al. (2016) reported paraesthesia in three out 
of 11 study subjects. No symptoms were reported for this dose in other studies (Stout et al., 
2007) although, as communicated later, about 20% of the subjects reported ‘‘tingling’’ 
sensations with beta-alanine in this study (J. Stout, personal communication, cited in: 
Décombaz et al., 2012). This illustrates that paraesthesia symptoms may be under-reported 
in some studies. When increasing beta-alanine doses to 2 g, Sweeney et al. (2010) reported 
‘‘no side effects other than a mild prickling sensation’’ in the neck and the limbs, while 
Bellinger and Minahan (2016) reported paraesthesia in a study of eight cyclists, two of which 
found the feelings uncomfortable or unpleasant. Macphee et al. (2013) gave a dose of 3 g 
beta-alanine to 20 study subjects; no response rate is given, but the data presented indicate 
that at least 15 out of 20 participants experienced paraesthesia, and one third of them 
characterised their symptoms as extremely bothersome. With single beta-alanine doses of 
3.2 g (40 mg/kg bw) and greater, side-effects were perceived as ‘‘unpleasant’’ (Harris et al., 
2006). Thus, it appears that a single doses up to 500 mg will be well tolerated, while a dose 
of 800 mg frequently will provoke mild, transient paraesthesia symptoms, and with higher 
doses the incidence and severity of paraesthesia will increase progressively.  
Another peculiarity is that after an interval of 2-3 hours since taking beta-alanine, plasma 
concentrations of beta-alanine have normalised, and a new dose will be tolerated. This may 
be repeated several times over the day (Harris et al., 2006). If paraesthesia is to be avoided, 
individual doses should therefore be 500 mg or lower for a 70 kg person. Higher daily doses 
should be split accordingly, and individual doses should be taken with 2-3 hour intervals. 
With slow-release preparations of beta-alanine, higher individual doses have been reported 
to be tolerated compared to the soluble powder form (Decombaz et al., 2012; Stellingwerff 
et al., 2012). 
 Human studies 
Table 2.4.1-1 An overview of human studies investigating beta-alanine and adverse health effects. 
Reference Study design/ 
participant 
characteristics 
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Reference Study design/ 
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The absorption of orally supplied beta-alanine and its effect on muscle carnosine 
synthesis in human vastus lateralis. Harris et al., 2006. 
Harris et al. (2006) performed a study where the absorption of orally supplied beta-alanine in 
its free form, or as carnosine in chicken broth, was examined in the context of beta-alanine 
blood concentrations and muscle carnosine synthesis. VKM has only considered the data 
from beta-alanine consumed in free form in the present report. 
Study 1: Six healthy male subjects with mean±SD age of 33.5 ±9.9 yrs and weighing 80.2 ± 
17.1 kg were recruited to this study where beta-alanine was administered at single doses of 
0, 10, 20 and 40 mg/kg bw. Plasma beta-alanine peaked after 30-40 min and regained 
baseline at 2-3 hours after administration. Subjects given 40 mg/kg bw of beta-alanine 
quickly complained of symptoms of flushing (described variously as an irritation of the skin 
and prickly sensation) which began within 20 minutes and lasted up to one hour after 
administration. As a result, the two lower doses of 10 and 20 mg/kg bw were introduced and 
similar symptoms were evident at 20 mg/kg bw and followed a similar time course, but were 
judged to be less intense. Mild symptoms of flushing were experienced by 2 of the 4 subjects 
taking 10 mg/kg bw. Based on this study, two additional studies (studies 2 and 3) were 
conducted.  
Study 2: The blood levels of beta-alanine were investigated in 6 males aged 28.3 + 2.7 years 
and weighing 83.2 +14.3 kg. Each subject was given three daily doses of 10 mg/kg bw beta-
alanine at 0, 3 and 6 h over a period of 15 days. The plasma concentration of beta-alanine 
peaked within 30-40 minutes of the intake and returned to baseline before the next intake. 
Notably, this repeated dosing did not give rise to any negative health affects apart from the 
occasional report of mild symptoms of flushing. 
Study 3: In the first part (pre-study), 8 male subjects for four weeks ingested four doses per 
day of 800 mg (10 mg/kg bw) beta-alanine in gelatine capsules (2 x 400 mg) at 9 am, 12 
am, 3 pm and 6 pm, giving a dose of 3.2 g/day, while 8 male subjects had a corresponding 
intake of placebo capsules (n=16, 19.4 ± SD 1.6 yrs; 79.5 ± 9.3 kg). The aim was to study 
effects of beta-alanine on haematology and clinical chemistry. It is stated that no clinically 
significant changes in 25 haematological and biochemical parameters were observed by the 
end of the 4-week period (results given, but statistical analysis not presented).  
For the second (main) part, to measure effects on muscle, twenty-one males (26.1 ±5.6 
years; 79.5 ±10.5 kg) were recruited. Of these, two groups (n=5) consumed beta-alanine 8 
times a day for four weeks (9, 10, 11, 12 am, 3, 4, 5, 6 pm), while a third group (n=6) took 
placebo (maltodextrin). One of the verum groups took 800 mg beta-alanine 4 times per day 
(daily dose 3.2 g) for four weeks. The other verum group took beta-alanine as follows: In 
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week one the subjects consumed a daily dose of 4 g (400 mg x 6 plus 800 mg x 2). In week 
two the daily dose was increased to 4.8 g (400 mg x 4 plus 800 mg x 4). In week three the 
daily dose was increased to 5.6 g (400 mg x 2 plus 800 mg x 6) whereas in week four the 
daily dose was increased to 6.4 g (800 mg x 8). There were no clinically significant 
symptoms during the study, apart from mild symptoms of flushing in some subjects (4 
subjects in week 2). One subject given the placebo also recorded mild symptoms of flushing. 
The authors stated that in later studies, involving about 50 subjects given 800 mg beta-
alanine (about 10 mg/kg bw) per day, about 25% of subjects reported mild or very mild 
paraesthesia symptoms. 
Influence of β-alanine supplementation on skeletal muscle carnosine 
concentrations and high intensity cycling capacity. Hill et al., 2007 
Hill et al. (2007) report a randomised, double blind, parallel-group, placebo-controlled study 
(n=25) on beta-alanine supplementation, with muscle carnosine levels and high-intensity 
cycling capacity as the main outcome. Subjects took placebo or beta-alanine 5 mg/kg bw x 6 
plus 10 mg/kg bw x 2 (daily dose 4.0 g) the first week, 5 mg/kg bw x 4 plus 10 mg/kg bw x 
4 (daily dose 4.8 g) the second week, 5 mg/kg bw x 2 plus 10 mg/kg bw x 6 (daily dose 5.6 
g) the third week, and 10 mg/kg bw x 8 (4.8 g/day) from week 4 through week 10 (7 
weeks). Thirteen participants stopped the experiment after week 4 by design, while 6 
participants taking verum and 6 taking placebo continued through week 10, i.e. for a total of 
7 weeks with the highest dose of 6.4 g/day. By design any side effects were to be recorded. 
Side effect-relevant blood analyses were not performed. Symptoms of paraesthesia were 
‘infrequent and mild’ when they occurred (number not given), no other adverse effects are 
reported.  
Effects of four weeks of β-alanine supplementation on repeated sprint ability in 
water polo players. Brisola et al., 2016 
Brisola et al. (2016) report a randomised, double blind, parallel-group, placebo-controlled 
study on beta-alanine supplementation, with repeated sprint ability in water polo players 
(n=27) as the main outcome. Subjects took beta-alanine 4.8 g/day (800 mg x 6) for 10 
days, then 6.4 g/day (1600 mg x 4) for 18 days. In the placebo group 2 subjects were lost to 
follow-up (injured), and in the verum group 3 subjects were lost (1 injured, 2 left the team), 
so that in each group 11 subjects were included in the analyses. Side effects were to be 
reported by design. Side effect-relevant blood analyses were not performed. Paraesthesia 
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Effect of two β—alanine dosing protocols on muscle carnosine synthesis and 
washout. Stellingwerff et al., 2012  
Stellingwerff et al. (2012) performed an eight-week placebo-controlled double-blind study in 
thirty-one young males randomised into three groups, receiving either 3.2 g (40 mg/kg bw) 
beta-alanine for four weeks followed by 1.6 g (20 mg/kg bw) beta-alanine for the next four 
weeks, 1.6 g beta-alanine for eight weeks, or placebo. Slow-release, 800-mg tablets were 
used. A wide range of haematology and clinical chemistry parameters were measured at 
baseline and at week 8. A questionnaire-based self-assessment of possible paraesthesia 
symptoms was conducted at weeks 0, 2, 4, and 8. A number of questionnaires were used, 
for body surface symptom score, profile of mood states, anxiety, and flushing symptoms. 
Participants had been pre-screened for re activity to a 400-mg dose (5 mg/kg bw) of a 
conventional beta-alanine preparation. Flushing symptoms and blood clinical chemistry 
findings were reported to be ‘trivial’ in all three groups in this pre-screened population, with 
no statistical differences. It should be noted that although plasma kinetics of beta-alanine 
and therefore presumably the risk of paraesthesia differs between conventional and slow-
release preparations, the area under the curve has been reported to be similar with 
conventional and slow-release beta-alanine preparations (Decombaz et al., 2012). Hence, 
the doses used in the present study are relevant in the discussion of potential toxicity (apart 
from paraesthesia) of conventional beta-alanine preparations. 
2.4.1.1 Interactions  
There was no information concerning interactions in the literature reviewed in the present 
risk assessment. The absence of information in the selected literature does not document an 
absence of interactions.  
2.4.1.2 Allergic sensitisation (including adjuvant effects) 
There was no information concerning allergic sensitisation or allergy adjuvant effects in the 
literature reviewed in the present risk assessment. Beta-alanine per se would not be 
expected to behave as an allergen. The absence of information in the selected literature 
does not document an absence of allergic sensitisation or allergy adjuvant effects. 
 Animal studies 
VKM considers that the available animal data are insufficient for use in the present report as 
they relay on experiments where beta-alanine has not been given in a free form, but as 
carnosine or peptide solutions. 
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 In vitro studies 
No in vitro studies of relevance were identified. 
 Mode of action for adverse effects  
Several possible mechanisms exist for the well-known side effect of paraesthesia, including 
beta-alanine activated strychnine-sensitive glycine receptor sites, associated with glutamate 
sensitive N-methyl-D-aspartate receptors in the brain and central nervous system (Mori et 
al., 2002; Tokutomi et al., 1989; Wang et al., 2003). Beta-alanine stimulation of nociceptive 
neurons is expected to be the transmitters of neuropathic pain. Moreover, it has been 
suggested that beta-alanine activates Mas-related genes (Mrg) or sensory neuron specific G-
protein coupled receptors (Shinohara et al., 2004). Specifically, MrgD, which is expressed in 
the dorsal root ganglion, terminates in the skin (Crozier et al., 2007) and it is likely that 
activation of MrgD from beta-alanine results in paraesthesia only in the skin. However, there 
is no evidence that the paraesthesia in the skin is harmful in any way apart from the 
discomfort (Bellinger and Minahan, 2016; Trexler et al., 2015).  
2.4.5. Vulnerable groups 
No vulnerable groups to excess doses of beta-alanine have been reported, apart from a 
preliminary study suggesting possible gender and ethnicity-dependent differences regarding 
paraesthesia (Macphee et al., 2013). There have been no reported studies involving children, 
elderly, pregnant women or lactating women.  
2.5 Summary of hazard identification and characterisation 
The only observed adverse effect from beta-alanine supplementation in humans is short-
lasting (60-120 min) paraesthesia (tingling, prickling, pin-and-needles sensation) that may 
be accompanied by flushing. There is no evidence that the paraesthesia and flushing in the 
skin is harmful (Bellinger and Minahan, 2016; Trexler et al., 2015), apart from the short-
lasting discomfort. The incidence and intensity of the discomfort appears to be dose-
dependent, and paraesthesia appears to occur rarely after a single dose smaller than 10 mg 
beta-alanine. This applies also if the dose is repeated after an interval of 2-3 hrs or more. 
The 10-mg dose of beta-alanine is frequently accompanied by mild paraesthesia. Higher 
doses may give stronger discomfort (Harris et al., 2006).  
In their 2006 paper, Harris et al. presented data from three placebo-controlled studies of 
healthy subjects consuming beta-alanine according to specific dosing regimens. A dose of 
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800 mg in 80-kg subjects i.e. 10 mg/kg bw four times daily over four weeks induced 
occasional symptoms of flushing, but no biologically relevant changes in 25 haematological 
and biochemical parameters. With increased frequency of beta-alanine intakes (8 doses 
daily, 400 and 800 mg doses) and incremental increase in the daily doses from 4 g the first 
week up to a maximum of 6.4 g the fourth week, four weeks of beta-alanine 
supplementation still produced only occasional episodes of flushing. 
In humans, paraesthesia may be provoked at intakes of beta-alanine of 10 mg/kg bw and 
higher. This implies that the individual dose of beta-alanine should not exceed 5 mg/kg bw 
(350 mg for a person of 70 kg bw), but this dose can be administered several times a day 
with 2-3 hour intervals as serum levels then have been normalised (Harris et al., 2006). If 
mild paraesthesia symptoms are seen as acceptable, single doses of 10 mg/kg bw taken with 
down to 1-hour intervals appear to be without other adverse health effects (Harris et al., 
2006) (Study 3, second part). 
The studies by Harris et al. (2006), Hill et al. (2007, and Brisola et al. (2016) indicate that 
given a proper splitting of the daily dose as discussed above, a daily dose of 6.4 g beta-
alanine in an 80-kg person (corresponding to 5.6 g or 80 mg/kg bw for a 70-kg person) for 
up to 7 weeks is unlikely to trigger adverse effects. With regard to haematology and clinical 
chemistry, support for this conclusion - although with half the dose of beta-alanine - is 
provided by the studies of Stellingwerff et al. (2012) and Harris et al. (2006). 
In summary, intake of individual doses of beta-alanine at 5 mg/kg bw or less is expected not 
to produce symptoms, whereas a dose of 10 mg/kg bw is associated with occasional mild 
symptoms of paraesthesia and flushing. Repeated intakes at 2-3 hour intervals of beta-
alanine with maximum 5 mg/kg bw per intake and a maximum daily dose of 6.4 g of beta-
alanine in an 80-kg person (corresponding to about 80 mg/kg bw per day, or 5.6 g in a 70 
kg adult) can be consumed without significant adverse health effects. VKM will in the present 
report use 80 mg/kg bw per day as the value of comparison.  
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3 Exposure / Intake 
Exposure to beta-alanine was estimated from the intake of food supplements. For food 
supplements, the intake was estimated for the age groups 10 to <14 years, 14 to <18 years 
and adults (≥18 years). 
3.1 Food supplements 
The Norwegian Food Safety Authority requested VKM to perform a risk assessment of 1000, 
1500 and 200 mg/day of beta-alanine in food supplement for children (10 – 17 years) and 
adults. The default body weights for age groups determined by EFSA were used: 10 to <14 
years = 43.4 kg, 14 to <18 years = 61.3 kg and adults = 70.0 kg. The exposures per kg bw 
are given in Table 3.1-1. 
Table 3.1-1 Estimated exposures of beta-alanine from specified doses in food supplements in 
children, adolescents and adults. 
Groups Beta-alanine,  




bw per day) 
Children  
(10 to <14 years) 
1000, 1500 and 
2000 
43.4 23.0, 34.6 and 46.1 
Adolescents  
(14 to <18 years) 
1000, 1500 and 
2000 
61.3 16.3, 24.5 and 32.6 
Adults  
(≥18 years) 
1000, 1500 and 
2000 
70.0 14.3, 21.4 and 28.6 
 
3.2 Other sources 
Foods rich in beta-alanine are in particular those prepared from skeletal muscle from 
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4 Risk characterisation  
The doses of beta-alanine in food supplement for which the Norwegian Food Safety 
Authority requested VKM to perform a risk assessment were 1000, 1500 and 2000 mg/day of 
for children (10 – 17 years) and adults. The default body weights for age groups determined 
by EFSA were used: 10 to <14 years = 43.4 kg, 14 to <18 years = 61.3 kg and adults = 
70.0 kg. 
Harris et al. (2006) gave 5 subjects (80 kg) stepwise increasing divided daily doses of 4.0 g, 
4.8 g, 5.6 g and 6.4 g (highest dose corresponding to 5.6 g or 80 mg/kg bw for a 70 kg 
person) over four weeks, with no adverse clinical effects observed other than occasional 
flushing. No haematological or blood clinical chemistry analyses were done. In the study by 
Hill et al. (2007), 6 subjects took beta-alanine 4.0 g for one week, followed by daily doses of 
4.8 g the second week and 5.6 g the third week. Thereafter, daily doses of 6.4 g 
(corresponding to 5.6 g or 80 mg/kg bw for a 70 kg person) were taken for 7 weeks. No 
adverse effects were noted other than symptoms of paraesthesia that were ‘infrequent and 
mild when they occurred’. Brisola et al. (2016) gave 14 subjects beta-alanine 4.8 g per day 
in divided doses for 10 days, followed by 18 days with a daily dose of 6.4 g beta-alanine 
(corresponding to 80 mg/kg bw). In the 11 participants included in the analysis, no adverse 
effects were reported except for infrequent and mild paraesthesia, which appears to be 
dependent on the single dose rather than the total daily dose (see above).  
Regarding laboratory parameters, in the study by Harris et al. (2006), beta-alanine 10 mg/kg 
bw x 4 per day (40 mg/kg bw or 2.8 g for a 70 kg person daily dose) for four weeks was 
found not to be associated with any significant change in haematology or clinical chemistry. 
There were no other signs and symptoms of any adverse effect, except for some cases of 
mild flushing (paraesthesia) that can be attributed to the magnitude of the individual doses. 
One other study can be considered as supportive with regard to haematology and clinical 
chemistry. Stellingwerff et al. (2012) with a slow-release preparation giving the same plasma 
level area-under-the-curve as regular soluble beta-alanine found that the dosage schemes of 
either 3.2 g beta-alanine per week for four weeks followed by 1.6 g beta-alanine for another 
four weeks or 1.6 g per day for 8 weeks gave no clinically relevant changes in 
haematological or clinical chemistry parameters.  
No adverse effects other than paraesthesia have been reported after beta-alanine intake, 
and general considerations of the metabolism of beta-alanine do not indicate any particular 
risk of adverse effects. Based on the studies by Harris et al. (2006), Hill et al. (2007), Brisola 
et al. (2016) and supported by the study of Stellingwerff et al. (2012), VKM will in the 
 
 
VKM Report 2017:13  30 
present report use 80 mg/kg bw per day (corresponding to 5.5 g for a 70 kg person) as the 
value of comparison (divided doses must be used, see above for magnitude of individual 
doses and dosing intervals). 
Our literature review did not reveal any studies of beta-alanine in children or adolescents, 
and there were no studies in children 10 years or older included in previous risk 
assessments. There are no data indicating that children and adolescents are more vulnerable 
than adults for beta-alanine.  
The margin of exposure (MOE-values) between 80 mg/kg bw per day and the exposures of 
beta-alanine from the specified food supplement doses, relevant for hypothetical adverse 
effects other than paraesthesia, are presented in Table 4-1. 
Table 4-1: The calculated margins between the value for comparison (80 mg/kg bw per day) and 
the exposure to beta-alanine from food supplements (MOE-values) for the various age groups. 






Children (10 to 
14 years) 
(43.4 kg) 
3.5 2.3 1.7 
Adolescents 
(14 to 18 
years) 
(61.3 kg) 




5.6 3.7 2.8 
The calculated MOE-values for data from the human studies ranged from 5.6 to 1.7 for a 
daily intake of 1000-2000 mg/day of supplemental beta-alanine.  
MOE-values below 10 in Table 4-1 (for interindividual differences in humans) were regarded 
as acceptable since beta-alanine is not known to cause any adverse health effects apart from 
the paraesthesia that is avoided by taking individual doses not exceeding 5 mg/kg bw, and 
since beta-alanine also is produced by the body and several foods contain significant 
amounts of beta-alanine.  
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VKM finds that it is unlikely that the specified doses of 1000, 1500 and 2000 mg of beta-
alanine in food supplements given to adults (> 18 years), adolescents (14 to <18 years) and 
children (10 to <14 years) will cause adverse health effects (provided that beta-alanine is 
consumed with 5 mg/kg bw or less per intake and with a minimum of 2 hours between the 
intakes). 
VKM considers that: 
 In adults (≥18 years), the specified doses 1000, 1500 and 2000 mg/day of beta-
alanine in food supplements are unlikely to cause adverse health effects provided 
that beta-alanine is consumed with 5 mg/kg bw per intake and preferably with 2 
hours between the intakes.  
 In adolescents (14 to <18 years) and children (10 to <14 years) the specified doses 
1000, 1500 and 2000 mg/day of beta-alanine in food supplements are unlikely to 
cause adverse health effects provided that beta-alanine is consumed with 5 mg/kg 
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5 Uncertainties 
The present risk assessment involves uncertainty related to: 
 the lack of long-term studies in humans reporting on potential adverse health effects 
of long-term beta-alanine supplementation at or above 80 mg/kg bw per day  
 Individual variation, as the quoted studies were small and mostly performed in males 
only, while some studies suggest gender and ethnic differences in susceptibility to 
paraesthesia 
 the fact that clinical chemistry and haematology data are available only for doses 
about half the magnitude of that used for comparison in the present report  
 the lack of studies on adolescents or children  
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6 Conclusions with answers to the 
terms of reference 
The Norwegian Food Safety Authority (NFSA) requested the Norwegian Scientific Committee 
for Food Safety (VKM) to assess the safety of beta-alanine at the specified doses 1000, 1500 
and 2000 mg/day in food supplements for the general population, ages 10 years and above. 
Based on data from three human studies and one supplementary study, a total daily intake 
of maximally 5.6 g (corresponding to 80 mg/kg bw per day in a 70 kg adult) for as long as 7 
weeks did not result in any adverse health effects. 
No particular vulnerable groups for beta-alanine supplements have been identified. 
VKM concludes that: 
 In adults (≥18 years), the specified doses 1000, 1500 and 2000 mg/day of beta-
alanine in food supplements are unlikely to cause adverse health effects provided 
that beta-alanine is consumed with maximum 5 mg/kg bw per intake and a minimum 
of 2 hours between the intakes.  
 In adolescents (14 to <18 years) and children (10 to <14 years) the specified doses 
1000, 1500 and 2000 mg/day of beta-alanine in food supplements are unlikely to 
cause adverse health effects provided that beta-alanine is consumed with maximum 5 
mg/kg bw per intake and a minimum of 2 hours between the intakes.  
An overview of the conclusions is presented in Table 6-1. 
Table 6-1: An overview of the conclusions for beta-alanine in food supplements.  
Green: Estimated exposures to beta-alanine are unlikely to cause adverse health effects. Note that 
 
 
VKM Report 2017:13  34 
these exposures are considered to be without adverse effects provided that beta-alanine is consumed 












(10 to <14 years) 
   
Adolescents  
(14 to <18 years) 
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7 Data gaps 
 There is a lack of studies focusing specifically on negative health effects related to 
beta-alanine taken over time in adults (> 18 years), adolescents (< 18 and > 10 
years) and children (> 10 years) 
 Studies using female subjects are essentially lacking 
 No studies are found that include effects of beta-alanine in potentially vulnerable 
groups (e.g. the elderly, pregnant and lactating women) 
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Appendix 1 
Search strategies for this risk assessment 
Search strategy human studies 
Database: Embase <1974 to 2016 September 13>, Ovid MEDLINE(R) In-Process & Other 
Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) <1946 to Present> 
1. alanine*.ti. (16574) 
2. alanine aminotransferase.ti. (2565) 
3. 1 not 2 (14009) 
4. (risk* or safety or adverse or side-effect*1 or hazard* or harm* or negative or 
contraindicat* or contra-indicat* or interact* or toxicity or toxic).tw. (10259252) 
5. 3 and 4 (2308) 
6. (conference abstract* or letter* or editorial*).pt. (5171367) 
7. 5 not 6 (2239)  
8. limit 7 to (danish or english or norwegian or swedish) (2188) 
9. limit 8 to human (580) 
10. remove duplicates from 9 (367) 
Search strategy animal studies 
Database: Embase <1974 to 2016 October 27>, Ovid MEDLINE(R) In-Process & Other Non-
Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) <1946 to Present> 
1. alanine*.ti. (16391) 
2. alanine aminotransferase.ti. (2595) 
3. 1 not 2 (13796) 
4. (risk* or safety or adverse or side-effect*1 or hazard* or harm* or negative or 
contraindicat* or contra-indicat* or interact* or toxicity or toxic).tw. (10393048) 
5. 3 and 4 (2326) 
6. (conference abstract* or letter* or editorial*).pt. (5207647) 
7. 5 not 6 (2256) 
8. limit 7 to (danish or english or norwegian or swedish) (2205) 
9. limit 8 to animals (555) 
10. remove duplicates from 9 (395) 
